Although the four major genes including the KRAS, TP53, SMAD4, and CDKN2A4 mutations that occur in PDAC are useful for monitoring the treatment response and course of diagnosed pancreatic cancer, it is difficult to use them for early diagnosis at this stage. This evidence concerns the gene KRAS and familial pancreatic carcinoma.